摘要
研究P选择素在胃癌、肾癌、肺癌、胶质瘤及卵巢肿瘤中表达的临床意义。应用免疫组化LSAB法分别检测P选择素在上述肿瘤中的表达。结果显示P选择素在上述肿瘤中阳性表达率分别为胃癌 5 3 3% (32 / 60例 )、肾癌 5 5 % (11/ 2 0例 )、肺癌 5 4% (2 7/ 5 0例 )、胶质瘤 61 5 % (2 4/ 39例 )、卵巢恶性肿瘤 5 3 3% (16/ 30例 )。P选择素不仅在肿瘤血管内皮上表达 ,亦在肿瘤细胞膜上表达。胃癌患者P选择素阳性者平均生存期和 5年生存率显著低于阴性者。此外 ,III、IV期肿瘤患者P选择素阳性表达率显著高于I、II期患者。P选择素与上述肿瘤的浸润转移相关 ,并可能是一种新的肿瘤转移及预后指标。
To investigate the clinical significance of P selectin expression in stomach carcinoma,renal cell carcinoma,lung carcinoma,glioma and ovarian carcinoma,the expression of P selectin levels in these patients were detected by LSAB immunohistochemistry in tissues of the above tumors The results revealed that the rates of P selectin expression were 53 3% (32/60) for stomach cancer,55%(11/20) for renal cell cancer,54%(27/50) for lung cancer,61 5%(24/39) for glioma,53 3%(16/30) for ovarian cancer respectively The positive expression of P selectin was higher in patients with advanced carcinomas (stage III and IV) than those with early stages (stage I and II) Furthermore,the statistical analysis showed that the survival period and five year survival rate were lower in gastric cancer with positive P selectin expression than that with negative one These results suggested that P selectin might play an important role in tumor metastasis and prognosis
出处
《上海免疫学杂志》
CSCD
北大核心
2000年第4期236-238,共3页
Shanghai Journal of Immunology
基金
卫生部科研基金资助项目!(No 94 2 2 4 5 )